Remotely Delivered Cancer Genetic Testing in the Making Genetic Testing Accessible (MAGENTA) Trial A Randomized Clinical Trial

被引:20
|
作者
Swisher, Elizabeth M. [1 ,13 ]
Rayes, Nadine [2 ]
Bowen, Deborah [3 ]
Peterson, Christine B. [4 ]
Norquist, Barbara M. [1 ]
Coffin, Tara [3 ]
Gavin, Kathleen [5 ]
Polinsky, Deborah [6 ]
Crase, Jamie [1 ]
Bakkum-Gamez, Jamie N. [7 ]
Blank, Stephanie V. [8 ]
Munsell, Mark F. [4 ]
Nebgen, Denise [2 ]
Fleming, Gini F. [9 ]
Olopade, Olufunmilayo I. [9 ]
Law, Sherman [10 ]
Zhou, Alicia [10 ]
Levine, Douglas A. [11 ,12 ]
D'Andrea, Alan [6 ]
Lu, Karen H. [2 ]
机构
[1] Univ Washington, Dept Obstet & Gynecol, Seattle, WA USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Gynecol, Houston, TX USA
[3] Univ Washington, Dept Bioeth & Humanities, Seattle, WA 98185 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX USA
[5] Minnesota Ovarian Canc Alliance, Minneapolis, MN USA
[6] Dana Farber Canc Inst, Boston, MA USA
[7] Mayo Clin, Dept Obstet & Gynecol, Rochester, MN USA
[8] Icahn Sch Med Mt Sinai, Dept Obstet Gynecol & Reprod Sci, New York, NY USA
[9] Univ Chicago Med, Sect Hematol & Oncol, Chicago, IL USA
[10] Color Hlth, Burlingame, CA USA
[11] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA
[12] Merck Res Labs, Rahway, NJ USA
[13] Univ Washington, Dept Obstet & Gynecol, 1959 NE Pacific St, POB 356460, Seattle, WA 98195 USA
关键词
IN-PERSON; NONINFERIORITY TRIAL; RISK-ASSESSMENT; FAMILY-HISTORY; TELEPHONE; IMPACT; BREAST; SUSCEPTIBILITY; PERCEPTIONS; PATIENT;
D O I
10.1001/jamaoncol.2023.3748
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
IMPORTANCE Requiring personalized genetic counselingmay introduce barriers to cancer risk assessment, but it is unknown whether omitting counseling could increase distress. OBJECTIVE To assess whether omitting pretest and/or posttest genetic counseling would increase distress during remote testing. DESIGN, SETTING, AND PARTICIPANTS Making Genetic Testing Accessible (MAGENTA) was a 4-arm, randomized noninferiority trial testing the effects of individualized pretest and/or posttest genetic counseling on participant distress 3 and 12 months posttest. Participants were recruited via social and traditional media, and enrollment occurred between April 27, 2017, and September 29, 2020. Participants were women aged 30 years or older, English-speaking, US residents, and had access to the internet and a health care professional. Previous cancer genetic testing or counseling was exclusionary. In the family history cohort, participants had a personal or family history of breast or ovarian cancer. In the familial pathogenic variant (PV) cohort, participants reported 1 biological relative with a PV in an actionable cancer susceptibility gene. Data analysis was performed between December 13, 2020, and May 31, 2023. INTERVENTION Participants completed baseline questionnaires, watched an educational video, and were randomized to 1 of 4 arms: the control arm with pretest and/or posttest genetic counseling, or 1 of 3 study arms without pretest and posttest counseling. Genetic counseling was provided by phone appointments and testing was done using home-delivered saliva kits. MAIN OUTCOMES AND MEASURES The primary outcomewas participant distress measured by the Impact of Event Scale 3 months after receiving the results. Secondary outcomes included completion of testing, anxiety, depression, and decisional regret. RESULTS A total of 3839 women (median age, 44 years [range 22-91 years]), most of whom were non-Hispanic White and college educated, were randomized, 3125 in the family history and 714 in the familial PV cohorts. In the primary analysis in the family history cohort, all experimental arms were noninferior for distress at 3 months. There were no statistically significant differences in anxiety, depression, or decisional regret at 3 months. The highest completion rates were seen in the 2 arms without pretest counseling. CONCLUSIONS AND RELEVANCE In the MAGENTA clinical trial, omitting individualized pretest counseling for all participants and posttest counseling for those without PV during remote genetic testing was not inferior with regard to posttest distress, providing an alternative care model for genetic risk assessment.
引用
收藏
页码:1547 / 1555
页数:9
相关论文
共 50 条
  • [21] Randomized trial of a decision aid for individuals considering genetic testing for hereditary nonpolyposis colorectal cancer risk
    Wakefield, Claire E.
    Meiser, Bettina
    Homewood, Judi
    Ward, Robyn
    O'Donnell, Sheridan
    Kirk, Judy
    CANCER, 2008, 113 (05) : 956 - 965
  • [22] A randomized controlled trial of a decision aid for women considering genetic testing for breast and ovarian cancer risk
    Wakefield, Claire E.
    Meiser, Bettina
    Homewood, Judi
    Peate, Michelle
    Taylor, Alan
    Lobb, Elizabeth
    Kirk, Judy
    Young, Mary-Anne
    Williams, Rachel
    Dudding, Tracy
    Tucker, Kathy
    BREAST CANCER RESEARCH AND TREATMENT, 2008, 107 (02) : 289 - 301
  • [23] A randomized controlled trial of a decision aid for women considering genetic testing for breast and ovarian cancer risk
    Claire E. Wakefield
    Bettina Meiser
    Judi Homewood
    Michelle Peate
    Alan Taylor
    Elizabeth Lobb
    Judy Kirk
    Mary-Anne Young
    Rachel Williams
    Tracy Dudding
    Kathy Tucker
    Breast Cancer Research and Treatment, 2008, 107 : 289 - 301
  • [24] Testing the Impact of a Peer-Delivered Family Support Program: A Randomized Clinical Effectiveness Trial
    Bearman, Sarah Kate
    Jamison, Jesslyn M.
    Lopez, Molly A.
    Baker, Nichole M.
    Sanchez, Joanne Emilia
    PSYCHIATRIC SERVICES, 2022, 73 (07) : 752 - 759
  • [25] Prospective trial of the clinical utility of genetic testing of selected neoplasms in surgical pathology
    Pfeifer, JD
    Hill, DA
    O'Sullivan, MJ
    Zhu, X
    Humphrey, PA
    Dehner, LP
    LABORATORY INVESTIGATION, 2001, 81 (01) : 17A - 17A
  • [26] Prospective trial of the clinical utility of genetic testing of selected neoplasms in surgical pathology
    Pfeifer, JD
    Hill, DA
    O'Sullivan, MJ
    Zhu, X
    Humphrey, PA
    Dehner, LP
    MODERN PATHOLOGY, 2001, 14 (01) : 17A - 17A
  • [27] PRENATAL AND POSTNATAL GENETIC TESTING AFTER PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) FOR A NON-SELECTION CLINICAL TRIAL.
    Tao, Xin
    Ma, Li
    Zhan, Yiping
    Tiegs, Ashley W.
    Whitehead, Christine V.
    Scott, Richard Thomas, Jr.
    Jalas, Chaim
    FERTILITY AND STERILITY, 2020, 114 (03) : E420 - E420
  • [28] The Michigan Genetic Hereditary Testing (MiGHT) study’s innovative approaches to promote uptake of clinical genetic testing among cancer patients: a study protocol for a 3-arm randomized controlled trial
    Lynette Hammond Gerido
    Jennifer J. Griggs
    Ken Resnicow
    Kelley M. Kidwell
    Emerson Delacroix
    Sarah Austin
    Erika N. Hanson
    Elizabeth Bacon
    Erika Koeppe
    Stefanie Goodall
    Matthew Demerath
    Elizabeth A. Rizzo
    Shayna Weiner
    Sarah T. Hawley
    Wendy R. Uhlmann
    J. Scott Roberts
    Elena M. Stoffel
    Trials, 24
  • [29] Genetic testing, predictive genetic testing for hereditary cancer
    Jonas, S
    Wild, C
    Schamberger, C
    VALUE IN HEALTH, 2003, 6 (06) : 794 - 795
  • [30] The Michigan Genetic Hereditary Testing (MiGHT) study's innovative approaches to promote uptake of clinical genetic testing among cancer patients: a study protocol for a 3-arm randomized controlled trial
    Gerido, Lynette Hammond
    Griggs, Jennifer J.
    Resnicow, Ken
    Kidwell, Kelley M.
    Delacroix, Emerson
    Austin, Sarah
    Hanson, Erika N.
    Bacon, Elizabeth
    Koeppe, Erika
    Goodall, Stefanie
    Demerath, Matthew
    Rizzo, Elizabeth A.
    Weiner, Shayna
    Hawley, Sarah T.
    Uhlmann, Wendy R.
    Roberts, J. Scott
    Stoffel, Elena M.
    TRIALS, 2023, 24 (01)